SCHEMBL570055

SCHEMBL570055

O=C(O)c1cc(-c2ccco2)[nH]n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 1.00
MEN1 O00255 6/20 1.00
KMT2A Q03164 6/20 1.00
POLB P06746 5/20 1.00
PDPK1 O15530 1/20 0.57
HPGD P15428 6/20 0.55
ALDH1A1 P00352 5/20 0.55
KDM4E B2RXH2 5/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
ALOX15 P16050 1/20 0.55
LMNA P02545 2/20 0.53
MME P08473 1/20 0.51
HTT P42858 3/20 0.50
GFER P55789 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
ALOX12 P18054 1/20 0.50
TDP1 Q9NUW8 3/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
CTDSP1 Q9GZU7 1/20 0.49
NPC1 O15118 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18555711 0.86 MAPT (0.75) MAPTMEN1KMT2APOLBPDPK1
SCHEMBL17742689 0.86 MAPT (0.75) MAPTMEN1KMT2APOLBPDPK1
SCHEMBL17773163 0.82 MAPT (0.69) MAPTMEN1KMT2APOLBPDPK1
SCHEMBL26450025 0.79 MAPT (0.64) MAPTMEN1KMT2APOLBPDPK1
SCHEMBL1430060 0.79 POLB (0.64) MAPTMEN1KMT2APOLBPDPK1
SCHEMBL69492 0.74 MEN1 (0.58) MAPTMEN1KMT2APOLBALDH1A1
SCHEMBL2736625 0.73 PDPK1 (0.64) MAPTMEN1KMT2APOLBPDPK1
SCHEMBL26905260 0.73 PDPK1 (0.64) MAPTMEN1KMT2APOLBPDPK1
Hydrochloric Acid SCHEMBL1221862 0.73 MEN1 (0.57) MAPTMEN1KMT2APOLBALDH1A1
SCHEMBL570420 0.73 PDPK1 (1.00) MAPTMEN1KMT2APOLBPDPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11993729-B2 Chemical mechanical polishing composition BASF SE (DE) 2024-05-28 US disclosed
EP-3714012-B1 CHEMICAL MECHANICAL POLISHING COMPOSITION BASF SE (DE) 2023-01-11 EP disclosed
CN-107922787-B Use of Chemical Mechanical Polishing (CMP) compositions for polishing cobalt-containing substrates 巴斯夫欧洲公司 2021-06-29 CN disclosed
US-20210102093-A1 USE OF A CHEMICAL MECHANICAL POLISHING (CMP) COMPOSITION FOR POLISHING OF COBALT COMPRISING SUBSTRATES BASF SE (DE) 2021-04-08 US disclosed
US-10899945-B2 Use of a chemical mechanical polishing (CMP) composition for polishing of cobalt comprising substrates BASF SE (DE) 2021-01-26 US disclosed
EP-3714012-A1 CHEMICAL MECHANICAL POLISHING COMPOSITION BASF SE (DE) 2020-09-30 EP disclosed
US-20200299547-A1 CHEMICAL MECHANICAL POLISHING COMPOSITION BASF SE (DE) 2020-09-24 US disclosed
CN-111356747-A Chemical mechanical polishing composition 巴斯夫欧洲公司 2020-06-30 CN disclosed
EP-3334794-B1 USE OF A CHEMICAL MECHANICAL POLISHING (CMP) COMPOSITION FOR POLISHING OF COBALT COMPRISING SUBSTRATES BASF SE (DE) 2020-02-19 EP disclosed
WO-2019101555-A1 CHEMICAL MECHANICAL POLISHING COMPOSITION BASF SE (DE) 2019-05-31 WO disclosed
EP-2601208-B1 LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY GRAFFINITY PHARMACEUTICALS GMBH (DE) 2015-02-11 EP disclosed
US-8518916-B2 Heterocyclic derivatives as M-GLU5 antagonists RECORDATI IRELAND LIMITED (IE) 2013-08-27 US disclosed
US-8518916-B2 Heterocyclic derivatives as M-GLU5 antagonists RECORDATI IRELAND LIMITED (IE) 2013-08-27 US disclosed
EP-2601208-A2 LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY Graffinity Pharmaceuticals GmbH (DE) 2013-06-12 EP disclosed
CN-103154018-A Ligands for antibody and Fc-fusion protein purification by affinity chromatography GRAFFINITY PHARMACEUTICALS GMBH 2013-06-12 CN disclosed
US-20130131321-A1 LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY GRAFFINITY PHARMACEUTICALS GMBH (DE) 2013-05-23 US disclosed
WO-2012017021-A2 LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY GRAFFINITY PHARMACEUTICALS GMBH (DE) 2012-02-09 WO disclosed
US-20090042841-A1 NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS RECORDATI IRELAND LIMITED (IE) 2009-02-12 US disclosed
US-20090042841-A1 NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS RECORDATI IRELAND LIMITED (IE) 2009-02-12 US disclosed
EP-1713778-B1 BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS GLAXO GROUP LTD (GB) 2008-01-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042841-A1 NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS GRM5, GRIK5, GRM3 MAPT 1249/4885MEN1 754/4885KMT2A 2216/4885
US-20130131321-A1 LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY FCGR1A, FCGR2A, FCER2 MAPT 4614/4885MEN1 3015/4885KMT2A 1127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.